Paxlovid for Treatment of Long Covid (STOP-PASC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05576662 |
Recruitment Status :
Completed
First Posted : October 12, 2022
Last Update Posted : October 10, 2023
|
Sponsor:
Stanford University
Collaborator:
Pfizer
Information provided by (Responsible Party):
Stanford University
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | October 10, 2022 | ||||||
First Posted Date ICMJE | October 12, 2022 | ||||||
Last Update Posted Date | October 10, 2023 | ||||||
Actual Study Start Date ICMJE | November 8, 2022 | ||||||
Actual Primary Completion Date | August 14, 2023 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Core Symptoms Severity Scale Score [ Time Frame: Week 10 ] This measure will evaluate whether there is a difference between treatment with Paxlovid versus placebo on any of the 6 core symptoms of PASC at week 10 (adjusting for patients' baseline levels). Each symptom (fatigue, brain fog, dyspnea, body aches, gastrointestinal symptoms, cardiovascular symptoms) is assessed on a 4-point Likert scale (range: 0 to 3; 0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms).
|
||||||
Original Primary Outcome Measures ICMJE |
Change in PROMIS Fatigue Score [ Time Frame: Baseline and week 10 ] PROMIS-Fatigue Short Form (SF 7a v1.0) is a 7-item scale developed by the Patient-Reported Outcome Measurement Information System (PROMIS). Respondents indicate how much they agree with fatigue item statements on a scale from 1 (not at all) to 5 (very much). Total scores are summed for a total score range from 7 to 35 with higher scores indicating greater fatigue.
|
||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Paxlovid for Treatment of Long Covid | ||||||
Official Title ICMJE | Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC | ||||||
Brief Summary | The purpose of this study is to compare whether being treated with Paxlovid (nirmatrelvir plus ritonavir) for 15 days works better than being treated with placebo (plus ritonavir) to reduce severe symptoms of Long Covid (the placebo does not have any active drug). Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid." |
||||||
Detailed Description | An exploratory sub-study will investigate the correlation of physical activity and biometric parameters from digital wearable devices with the subjective symptom severity and other patient-reported outcomes in the main study. All participants with iPhone 6S Plus or newer will be offered an opportunity to opt-in to this sub-study. An Apple Watch and Bluetooth-enabled blood pressure monitor will be provided to participants and data will be collected for the duration of the main study to track participants' physiological and behavioral trends in the Paxlovid versus placebo groups. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
168 | ||||||
Original Estimated Enrollment ICMJE |
200 | ||||||
Actual Study Completion Date ICMJE | September 12, 2023 | ||||||
Actual Primary Completion Date | August 14, 2023 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT05576662 | ||||||
Other Study ID Numbers ICMJE | 66994 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | Stanford University | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Stanford University | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | Pfizer | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Stanford University | ||||||
Verification Date | October 2023 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |